Canada markets closed

FSD Pharma Inc. (HUGE.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
2.1500-0.0700 (-3.15%)
At close: 3:59PM EST

FSD Pharma Inc.

First Canadian Place
Suite 3400 100 King Street West
Toronto, ON M5X 1A4

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees17

Key Executives

NameTitlePayExercisedYear Born
Dr. Raza Bokhari M.B.A., M.D., MBAExec. Chairman & CEO1N/A1968
Mr. Anthony John DurkaczFounder & DirectorN/AN/A1976
Mr. Donal Carroll CPAChief Financial Officer58.67kN/A1977
Dr. Sara May Ph.D.Sr. VPN/AN/AN/A
Dr. Sandra R. LottesVP & Head of Clinical Research of FSD BioSciences, IncN/AN/AN/A
Ms. Maryann AdessoChief of StaffN/AN/AN/A
Dr. Edward J. Brennan Jr., F.A.C.S., M.D., FACSPres of FSD BioSciences, IncN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.

Corporate Governance

FSD Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.